

# Pascale A Cohen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/965145/publications.pdf>

Version: 2024-02-01

37  
papers

2,069  
citations

279798

23  
h-index

345221

36  
g-index

38  
all docs

38  
docs citations

38  
times ranked

3706  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 647269.	2.8	2
2	Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay. <i>Frontiers in Oncology</i> , 2020, 10, 712.	2.8	13
3	The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX <sup>®</sup> Recurrence Score in ER-Positive Invasive Breast Cancers. <i>Frontiers in Pharmacology</i> , 2019, 10, 524.	3.5	3
4	The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice. <i>Frontiers in Pharmacology</i> , 2019, 10, 667.	3.5	11
5	Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2773.	4.1	13
6	Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 1581.	3.5	11
7	The critical role of the <scp>ZNF217</scp> oncogene in promoting breast cancer metastasis to the bone. <i>Journal of Pathology</i> , 2017, 242, 73-89.	4.5	42
8	Long-term exposure to bisphenol A or benzo(a)pyrene alters the fate of human mammary epithelial stem cells in response to BMP2 and BMP4, by pre-activating BMP signaling. <i>Cell Death and Differentiation</i> , 2017, 24, 155-166.	11.2	39
9	LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers. <i>Cancer Research</i> , 2016, 76, 3541-3552.	0.9	28
10	MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 13.	5.0	69
11	The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value. <i>Oncotarget</i> , 2015, 6, 41566-41581.	1.8	50
12	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIRO1/UNICANCER). <i>Lancet Oncology</i> , The, 2014, 15, 267-274.	10.7	351
13	A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers. <i>Molecular Oncology</i> , 2014, 8, 1441-1457.	4.6	32
14	Learning the local Bayesian network structure around the ZNF217 oncogene in breast tumours. <i>Computers in Biology and Medicine</i> , 2013, 43, 334-341.	7.0	8
15	CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 19525-19530.	7.1	73
16	Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of <i>de novo</i> or acquired resistance and importance of combining the allosteric Akt inhibitor MK&€2206 with an aromatase inhibitor. <i>International Journal of Cancer</i> , 2013, 133, 1589-1602.	5.1	42
17	ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial&€“Mesenchymal Transition and Invasion. <i>Cancer Research</i> , 2012, 72, 3593-3606.	0.9	107
18	Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors. <i>Endocrine Reviews</i> , 2011, 32, 597-622.	20.1	244

#	ARTICLE	IF	CITATIONS
19	MRP8/ABCC11 Expression Is Regulated by Dexamethasone in Breast Cancer Cells and Is Associated to Progesterone Receptor Status in Breast Tumors. <i>International Journal of Breast Cancer</i> , 2011, 2011, 1-6.	1.2	6
20	Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. <i>International Journal of Cancer</i> , 2010, 126, 545-562.	5.1	110
21	Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2010, 5, 29-57.	1.6	136
22	ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. <i>Molecular Cancer</i> , 2010, 9, 291.	19.2	42
23	Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. <i>Journal of Molecular Endocrinology</i> , 2009, 42, 87-103.	2.5	65
24	mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene expression levels. <i>Cancer Science</i> , 2008, 99, 1992-2003.	3.9	66
25	A candidate molecular signature associated with tamoxifen failure in primary breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R88.	5.0	54
26	ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor $\beta$ expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. <i>Endocrine-Related Cancer</i> , 2008, 15, 125-138.	3.1	30
27	Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 375, 308-314.	2.1	42
28	Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications. <i>BMC Cancer</i> , 2003, 3, 13.	2.6	77
29	Intrabodies: Targeting scFv Expression to Eukaryotic Intracellular Compartments. , 2002, 178, 367-378.		15
30	Interaction of the octapeptide angiotensin II with a high-affinity single-chain Fv and with peptides derived from the antibody paratope. <i>Journal of Immunological Methods</i> , 2001, 254, 147-160.	1.4	11
31	Monitoring Cellular Responses to <i>Listeria monocytogenes</i> with Oligonucleotide Arrays. <i>Journal of Biological Chemistry</i> , 2000, 275, 11181-11190.	3.4	106
32	Biochemical characterization of different conformational states of the Sf9 cell-purified p53His175 mutant protein. <i>FEBS Letters</i> , 1999, 463, 179-184.	2.8	13
33	Characterization of a new intrabody directed against the N-terminal region of human p53. <i>Oncogene</i> , 1998, 17, 2445-2456.	5.9	57
34	Systematic Exploration of the Antigen Binding Activity of Synthetic Peptides Isolated from the Variable Regions of Immunoglobulins. <i>Journal of Biological Chemistry</i> , 1997, 272, 30937-30944.	3.4	71
35	The Natural Mutation Y248C of Human Angiotensinogen Leads to Abnormal Glycosylation and Altered Immunological Recognition of the Protein. <i>Journal of Biological Chemistry</i> , 1996, 271, 9838-9844.	3.4	16
36	New monoclonal antibodies directed against the propart segment of human prorenin as a tool for the exploration of prorenin conformation. <i>Journal of Immunological Methods</i> , 1995, 184, 91-100.	1.4	7

#	ARTICLE	IF	CITATIONS
37	Environmental pollutants-dependent molecular pathways and carcinogenesis. <i>BioDiscovery</i> , 0, 22, .	0.1	0